Tamoxifen, one of the most popular SERMs, acts as an ER agonist in bone and uterus but also as an ER antagonist in the breast; therefore, it has been an effective adjuvant endocrine therapy for breast cancer for more than 30 years [7]. Here, ESR1 is linked to breast carcinoma.